TY  - JOUR
AU  - Rivera, Fernando
AU  - Karthaus, Meinolf
AU  - Hecht, J Randolph
AU  - Sevilla, Isabel
AU  - Forget, Frédéric
AU  - Fasola, Gianpiero
AU  - Canon, Jean-Luc
AU  - Guan, Xuesong
AU  - Demonty, Gaston
AU  - Schwartzberg, Lee S
PY  - 2017
DO  - 10.1007/s00384-017-2800-1
UR  - http://hdl.handle.net/10668/11115
T2  - International journal of colorectal disease
AB  - To report planned final overall (OS) and progression-free survival (PFS) analyses from the phase II PEAK trial (NCT00819780). Patients with previously untreated, KRAS exon 2 wild-type (WT) metastatic colorectal cancer (mCRC) were randomised to...
LA  - en
KW  - Bevacizumab
KW  - First-line
KW  - Metastatic colorectal cancer
KW  - Overall survival
KW  - Panitumumab
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - Colorectal Neoplasms
KW  - Demography
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Panitumumab
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Young Adult
TI  - Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
TY  - research article
VL  - 32
ER  -